Today: 11 November 2025
Subscribe

Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Axsome Therapeutics (AXSM) Skyrockets on CNS Breakthroughs: Stock Surge, Pipeline Wins, and 2025 Outlook

Axsome Therapeutics (AXSM) Skyrockets on CNS Breakthroughs: Stock Surge, Pipeline Wins, and 2025 Outlook

Stock Performance and Recent Trend Axsome’s stock has been a standout performer in 2025. As of November 3, 2025, AXSM trades around $134–$135 per share, roughly doubling from its 52-week low of $75.56 finviz.com. The stock has gained about 60% year-to-date and 52% over the past year seattlepi.com – a remarkable run that far outpaces the broader biotech sector and the S&P 500. This surge reflects growing investor optimism as Axsome transforms into a commercial-stage company with multiple marketed drugs. Recent trading momentum: In the days leading up to Nov 3, AXSM shares climbed steadily, likely in anticipation of strong
3 November 2025
 ·  ·  ·  ·  · 
ClearPoint Neuro (CLPT) Stock Skyrockets on Brain Therapy Breakthroughs – 2025 Deep Dive

ClearPoint Neuro (CLPT) Stock Skyrockets on Brain Therapy Breakthroughs – 2025 Deep Dive

Stock Performance & Trading Trends (2025) ClearPoint Neuro’s stock has delivered dramatic gains in 2025, transforming from a little-known small-cap into a high-flyer. The share price rallied over 300% from 2024 lows, driven by positive news in both the company’s own product line and its partners’ clinical trial successes. Notably, CLPT climbed from roughly $5.50 in May 2024 to over $19 by February 2025 nasdaq.com. After a mid-year breather, momentum returned in Q3/Q4 2025: the stock surged nearly 40% in one day on September 24, 2025 after announcing an FDA clearance (for its Prism laser) and bullish revenue guidance nasdaq.com
3 November 2025
 ·  ·  ·  · 
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Analyst outlook & forecast: Long-term, analysts model robust growth. For example, one financial model projects ~18% revenue CAGR: ~$3.3 billion in sales by 2028 and ~$261 million net income simplywall.st. Another estimate sees revenue rising from ~$2.35 B in 2025 to ~$3.34 B by 2027 tipranks.com, and free cash flow turning positive in 2025 simplywall.st. These forecasts assume continued momentum in weight-loss/metabolic services plus gains in new verticals. Yet many investors note the high valuation (HIMS trades near ~$45 with market cap in the billions) and regulatory/legal risks. Community “fair value” estimates vary widely (some as low as $41) due to uncertainty simplywall.st. Key
3 November 2025
 ·  ·  ·  ·  · 
CURE Pharmaceutical (CURR) Stock Skyrockets Amid Wellness Pivot – What’s Next for Investors?

CURE Pharmaceutical (CURR) Stock Skyrockets Amid Wellness Pivot – What’s Next for Investors?

High-Flying Share Price and Recent Performance 🚀 As of November 3, 2025, CURE Pharmaceutical’s stock is trading around $3.6 per share, reflecting an explosive rise in late October. On Friday, Oct 31, the stock closed at $3.78, up from $2.89 the day prior stockinvest.us. That single-day gain of +30.8% crowned CURR (now AVRW) as one of the market’s top percentage gainers. In fact, the stock has rallied five days in a row, more than doubling (+104% in two weeks) amid surging volume stockinvest.us. This momentum continued into Nov 3, with an opening trade around $3.52 and only a modest pullback
3 November 2025
 ·  ·  ·  · 
Nocera (NCRA) Stock Skyrockets 36% on $300M Digital Asset Deal – Key Facts & Outlook

Nocera (NCRA) Stock Skyrockets 36% on $300M Digital Asset Deal – Key Facts & Outlook

Company Overview and Business Model Nocera is a small-cap company that began in the aquaculture technology niche. It designs and builds land-based recirculating aquaculture systems (RAS) – essentially the tanks, filtration equipment, and engineering needed for sustainable fish farms stockanalysis.com. Founded in 2014 and based in New Taipei City, Taiwan, Nocera provided engineering, procurement, and construction services to fish farming projects, aiming to make seafood production more efficient on land stockanalysis.com. In 2023–2024, Nocera branded itself as a “fully integrated sustainable seafood company,” but it has since broadened its scope. Now the firm calls itself “dynamic, industry-agnostic, and acquisition-focused,” seeking
3 November 2025
 ·  ·  ·  ·  · 
TG Therapeutics Stock Soars on Briumvi Boom – Key Facts, Analyst Insights & 2025 Outlook

TG Therapeutics Stock Soars on Briumvi Boom – Key Facts, Analyst Insights & 2025 Outlook

Company Overview: Briumvi-Focused Business Model TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in treatments for B-cell mediated diseases gurufocus.com. After years as a development-stage biotech, TG entered the commercial arena with Briumvi, its first approved product, and now generates the majority of revenue from Briumvi sales in the U.S. gurufocus.com. The company’s strategy centers on leveraging its expertise in B-cell biology to address both autoimmune disorders and B-cell cancers. Briumvi – A Breakthrough in Multiple Sclerosis Therapy Briumvi (ublituximab-xiiy) is TG’s flagship drug, approved by the FDA in December 2022 for adults with relapsing forms of multiple sclerosis
3 November 2025
 ·  ·  ·  ·  · 
Dominion Energy’s Q3 Shocker: Data Center Boom and Offshore Wind Pay Off in Surging Profits

Dominion Energy’s Q3 Shocker: Data Center Boom and Offshore Wind Pay Off in Surging Profits

Dominion Delivers an Earnings Beat in Q3 2025 Dominion Energy turned in strong third-quarter 2025 results, surpassing analyst expectations on the bottom line. The utility reported net income of $1.0 billion for Q3 (about $1.16 per share), up from $934 million ($1.09) in the same quarter a year ago news.dominionenergy.com. On an operating basis (excluding one-time items), earnings were $921 million, or $1.06 per share, comfortably beating consensus estimates in the mid-$0.90s range news.dominionenergy.com reuters.com. This performance marked roughly an 8% increase in per-share earnings year-over-year – a notable achievement for a regulated utility. Revenue also leapt 14.9% to $4.53 billion from $3.94 billion in
3 November 2025
 ·  ·  ·  ·  · 
Biohaven Stock’s Wild Ride: Big Drops, Big Hopes as FDA Verdict Nears

Biohaven Stock’s Wild Ride: Big Drops, Big Hopes as FDA Verdict Nears

In summary, Biohaven’s stock is a tale of high stakes in biotech. Recent price swings underscore the uncertainty, but also the potential reward if Biohaven’s bets pay off. With an FDA verdict looming and multiple shots on goal in its pipeline, investors should brace for more turbulence. The company’s strong institutional backing and “Strong Buy” analyst consensus indicate confidence in the science investing.com directorstalkinterviews.com. Still, caution is warranted – Biohaven will need to deliver clinical and regulatory wins to justify those bullish forecasts. In the coming weeks, news flow (FDA decision, earnings, trial readouts) could rapidly shift the narrative yet
3 November 2025
 ·  ·  ·  ·  · 
Iovance Biotherapeutics (IOVA): TIL Cancer Breakthrough or Biotech Bust?

Iovance Biotherapeutics (IOVA): TIL Cancer Breakthrough or Biotech Bust?

Company Overview: Pioneering TIL Therapy in Oncology Iovance Biotherapeutics is focused on developing tumor-infiltrating lymphocyte (TIL) therapies – a novel form of immunotherapy where a patient’s own T cells, harvested from their tumor, are expanded and activated in a lab, then reinfused to attack cancer. This approach, originally pioneered by NCI’s Dr. Steven Rosenberg in the 1980s, finally reached fruition when Iovance’s lifileucel (brand name Amtagvi) earned FDA approval in 2024 as the first-ever TIL therapy (and the first cellular therapy for any solid tumor) cancer.gov. Lifileucel is indicated for unresectable or metastatic melanoma that has progressed after standard immunotherapies
3 November 2025
 ·  ·  ·  ·  · 
Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Company Background and Business Model Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company specializing in RNA interference (RNAi) therapies for cancer. The company was co-founded by Nobel laureate Dr. Craig Mello, a discoverer of RNAi, leveraging that legacy to develop its proprietary INTASYL™ gene-silencing technology phiopharma.com. Originally known as RXi Pharmaceuticals (founded ~2011), Phio rebranded and refocused on immuno-oncology. Its mission is to use small interfering RNA (siRNA) to “silence” genes that allow tumors to evade the immune system, thereby empowering the body’s own defenses to fight cancer ragingbull.com. Headquartered in Pennsylvania (King of Prussia) with R&D roots in Massachusetts,
3 November 2025
 ·  ·  ·  ·  · 
ON Semiconductor (ON) Stock Surges on Q3 Earnings Beat – Latest News, Financials, and Outlook

ON Semiconductor (ON) Stock Surges on Q3 Earnings Beat – Latest News, Financials, and Outlook

Recent News and Updates (Early November 2025) Earnings Release: On November 3, 2025, ON Semiconductor announced its third-quarter 2025 financial results, which were better than expected. The company reported Q3 revenue of $1.55 billion (down roughly 11% year-over-year) and a profit of $255 million timesunion.com timesunion.com. Earnings came out to $0.63 per diluted share, beating Wall Street’s consensus of $0.60. This marks a positive surprise given the headwinds the company faced earlier in the year. Management noted that the results “exceeded expectations, underscoring the strength of our strategy and the resilience of our business model,” according to CEO Hassane El-Khoury tradingview.com. He
3 November 2025
 ·  ·  ·  · 
UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

Stock Performance: Skyrockets and Crashes UniQure’s stock has been on a wild ride in 2025. After starting the year in the mid-teens, QURE shares skyrocketed through mid-2025 on hopes for its Huntington’s gene therapy. The rally hit a fever pitch in late September when Phase 1/2 trial data showed a remarkable 75% reduction in disease progression with AMT-130 – news that caused the stock to surge almost 200% that month reuters.com. By late October, QURE was hovering around $68–$70, up roughly 300–500% from spring levels. However, in the past few days the stock’s momentum sharply reversed. On Monday, Nov 3,
3 November 2025
 ·  ·  ·  ·  · 
1 … 23 24 25 26 27 … 175
Go toTop